[{"id":"f3ef9fae-5b75-49a9-8d7a-d7fd466912a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03992911","created_at":"2021-01-18T19:37:48.561Z","updated_at":"2024-07-02T16:36:58.743Z","phase":"Phase 2/3","brief_title":"Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma","source_id_and_acronym":"NCT03992911","lead_sponsor":"Peking University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • etoposide IV • simmitecan"],"overall_status":"Recruiting","enrollment":" Enrollment 336","initiation":"Initiation: 06/19/2019","start_date":" 06/19/2019","primary_txt":" Primary completion: 06/20/2022","primary_completion_date":" 06/20/2022","study_txt":" Completion: 06/20/2023","study_completion_date":" 06/20/2023","last_update_posted":"2019-06-20"}]